相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Minimal Inhibitory Concentration of Clofazimine Among Clinical Isolates of Nontuberculous Mycobacteria and Its Impact on Treatment Outcome
Nakwon Kwak et al.
CHEST (2021)
What are the challenges in commercial non-tuberculous mycobacteria (NTM) drug discovery and how should we move forward?
Graham S. Timmins
EXPERT OPINION ON DRUG DISCOVERY (2020)
Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill
Tawanda Gumbo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
How to design a study to evaluate therapeutic drug monitoring in infectious diseases?
A-G Martson et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
State-of-the-art treatment strategies for nontuberculous mycobacteria infections
Maria-Carmen Munoz-Egea et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Mohd H. Abdul-Aziz et al.
INTENSIVE CARE MEDICINE (2020)
Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii
Moti Chapagain et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline
Charles L. Daley et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Clofazimine pharmacokinetics in patients with TB: dosing implications
Mahmoud Tareq Abdelwahab et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large US Managed Care Health Plan, 2008-2015
Kevin L. Winthrop et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2020)
Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections
Brandon Banaschewski et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Antimicrobial Susceptibility of Clinical and Environmental Mycobacterium chimaera Isolates
Simone Mok et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic
Steven Opal et al.
CLINICAL INFECTIOUS DISEASES (2019)
Non-tuberculous mycobacterial pulmonary disease
Steven Cowman et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Repositioning rifamycins for Mycobacterium abscessus lung disease
Uday S. Ganapathy et al.
EXPERT OPINION ON DRUG DISCOVERY (2019)
Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria
Barbara A. Brown-Elliott et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2019)
Prevalence, incidence, and mortality of nontuberculous mycobacterial infection in Korea: a nationwide population-based study
Seon Cheol Park et al.
BMC PULMONARY MEDICINE (2019)
Pharmacotherapy Approaches in Nontuberculous Mycobacteria Infections
Jennifer A. Shulha et al.
MAYO CLINIC PROCEEDINGS (2019)
Nontuberculosis mycobacteria infections: would there be pharmacodynamics without pharmacokinetics?
Hannah Yejin Kim et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases
Hee Jae Huh et al.
INFECTION GENETICS AND EVOLUTION (2019)
A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria
Mike Marvin Ruth et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
MIC-based dose adjustment: facts and fables
Johan W. Mouton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Clofazimine for the treatment of Mycobacterium kansasii
Shashikant Srivastava et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
The stability of antimycobacterial drugs in media used for drug susceptibility testing
Esther L. M. Schoutrop et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis
K. E. Stott et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens
Eun Hye Cho et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2018)
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis
Devyani Deshpande et al.
CLINICAL INFECTIOUS DISEASES (2018)
Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment
Marieke G. G. Sturkenboom et al.
CLINICAL INFECTIOUS DISEASES (2018)
Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system
Vitalii Litvinov et al.
PLOS ONE (2018)
Treatment of Other Nontuberculous Mycobacteria
Damien Basille et al.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
In Vitro Susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum Isolates to 30 Antibiotics
Yaojie Shen et al.
BIOMED RESEARCH INTERNATIONAL (2018)
Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity
Jose R. Yuste et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease
David C. Alexander et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2017)
Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Combined Species Identification and Drug Sensitivity Testing in Mycobacteria
Pieter-Jan Ceyssens et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2017)
Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus
Amit Kaushik et al.
FUTURE MICROBIOLOGY (2017)
Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria
Guilian Li et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Effect of β-lactamase production and β-lactam instability on MIC testing results for Mycobacterium abscessus
Anna Rominski et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance
Shashikant Srivastava et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent
Devyani Deshpande et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Linezolid as treatment for pulmonary Mycobacterium avium disease
Devyani Deshpande et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease
Devyani Deshpande et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria
Faiza Mougari et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria
Barbara A. Brown-Elliott et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2017)
In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria
Diana A. Aguilar-Ayala et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2017)
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)
Charles S. Haworth et al.
THORAX (2017)
British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)
Charles S. Haworth et al.
BMJ OPEN RESPIRATORY RESEARCH (2017)
The macrolide antibiotic renaissance
George P. Dinos
BRITISH JOURNAL OF PHARMACOLOGY (2017)
In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China
Yu Pang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Rifabutin Is Active against Mycobacterium abscessus Complex
Dinah Binte Aziz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA
Yosra Alkabab et al.
BMC INFECTIOUS DISEASES (2017)
Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model
Beatriz E. Ferro et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis
R. Andres Floto et al.
THORAX (2016)
Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease
Beatriz E. Ferro et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease
Beatriz E. Ferro et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease
Devyani Deshpande et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection
Beatriz E. Ferro et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease
Seong Mi Moon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin
Julie Jarand et al.
CHEST (2016)
Successful treatment of methicillin-resistant Staphylococcus aureus osteomyelitis with combination therapy using linezolid and rifampicin under therapeutic drug monitoring
Nobuyuki Ashizawa et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2016)
Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' Perspectives
Yon Ju Ryu et al.
TUBERCULOSIS AND RESPIRATORY DISEASES (2016)
Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases
Kozo Morimoto et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2016)
Rapid Drug Tolerance and Dramatic Sterilizing Effect of Moxifloxacin Monotherapy in a Novel Hollow-Fiber Model of Intracellular Mycobacterium kansasii Disease
Shashikant Srivastava et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease
Julie V. Philley et al.
CHEST (2015)
Medications and Monitoring in Nontuberculous Mycobacteria Infections
Eric F. Egelund et al.
CLINICS IN CHEST MEDICINE (2015)
Pathogenesis and Risk Factors for Nontuberculous Mycobacterial Lung Disease
Jennifer R. Honda et al.
CLINICS IN CHEST MEDICINE (2015)
Epidemiology of Human Pulmonary Infection with Nontuberculous Mycobacteria A Review
D. Rebecca Prevots et al.
CLINICS IN CHEST MEDICINE (2015)
Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis
J. A. Dijkstra et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease
Beatriz E. Ferro et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Pharmacokinetic-Pharmacodynamic and Dose-Response Relationships of Antituberculosis Drugs: Recommendations and Standards for Industry and Academia
Tawanda Gumbo et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Time-kill kinetics of antibiotics active against rapidly growing mycobacteria
Beatriz E. Ferro et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
β-Lactamase inhibition by avibactam in Mycobacterium abscessus
Vincent Dubee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients
Mathieu S. Bolhuis et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples An NTM-NET collaborative study
Wouter Hoefsloot et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence
Jakko van Ingen et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2013)
Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections
C. Magis-Escurra et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
Comparative Drug Resistance of Mycobacterium abscessus and M. chelonae Isolates from Patients with and without Cystic Fibrosis in the United Kingdom
Agnieszka Broda et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2013)
The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium avium Complex Disease Treatment
Jakko van Ingen et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Therapeutic Drug Monitoring in the Treatment of Mycobacterium avium Complex Lung Disease
Won-Jung Koh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2012)
Novel Antibiotics Targeting Respiratory ATP Synthesis in Gram-Positive Pathogenic Bacteria
Wendy Balemans et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
In Vitro Synergy between Clofazimine and Amikacin in Treatment of Nontuberculous Mycobacterial Disease
Jakko van Ingen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Antimicrobial Susceptibility Testing, Drug Resistance Mechanisms, and Therapy of Infections with Nontuberculous Mycobacteria
Barbara A. Brown-Elliott et al.
CLINICAL MICROBIOLOGY REVIEWS (2012)
Phase 2, Randomized, Double-Blind, Dose-Ranging Study Evaluating the Safety, Tolerability, Population Pharmacokinetics, and Efficacy of Oral Torezolid Phosphate in Patients with Complicated Skin and Skin Structure Infections
P. Prokocimer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens
Shashikant Srivastava et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability
Shashikant Srivastava et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Review of Macrolides (Azithromycin, Clarithromycin), Ketolids (Telithromycin) and Glycylcyclines (Tigecycline)
Jerry M. Zuckerman et al.
MEDICAL CLINICS OF NORTH AMERICA (2011)
Moxifloxacin Pharmacokinetics/Pharmacodynamics and Optimal Dose and Susceptibility Breakpoint Identification for Treatment of Disseminated Mycobacterium avium Infection
Devyani Deshpande et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Ethambutol Optimal Clinical Dose and Susceptibility Breakpoint Identification by Use of a Novel Pharmacokinetic-Pharmacodynamic Model of Disseminated Intracellular Mycobacterium avium
Devyani Deshpande et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Comparison of the Pharmacokinetics of Two Dosage Regimens of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Patients
Jan-Willem C. Alffenaar et al.
CLINICAL PHARMACOKINETICS (2010)
In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The Netherlands
Jakko van Ingen et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Clinical Outcome of Mycobacterium abscessus Infection and Antimicrobial Susceptibility Testing
Yi-Ching Huang et al.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2010)
Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
Scott K. Heysell et al.
EMERGING INFECTIOUS DISEASES (2010)
ATP Synthase Inhibition of Mycobacterium avium Is Not Bactericidal
Nacer Lounis et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases
David E. Griffith et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans
Baohong Ji et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline
JE Conte et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2005)
Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics - The minimum inhibitory concentration versus stationary concentration
JW Mouton et al.
CLINICAL PHARMACOKINETICS (2005)
Aminoglycoside toxicity: Daily versus thrice-weekly dosing for treatment of mycobacterial diseases
CA Peloquin et al.
CLINICAL INFECTIOUS DISEASES (2004)
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling
T Gumbo et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid
DE Nix et al.
TUBERCULOSIS (2004)
Comparison of the in vitro activity (formerly GAR-936) with those of tetracycline, minocycline, and deoxycycline against isolates of nontuberculous mycobaceria
RJ Wallace et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
分享论文
